semaglutide
India’s GLP‑1 Tug‑of‑War: How a 40% Price Gap Is Redrawing the Semaglutide Map
Semaglutide delivers a 14.9 kg average weight loss in the STEP-5 trial, eclipsing tirzepatide’s 13.4 kg (p=0.02). Yet, in India the drug’s premium aura is being challenged by a 40-41% price gap that could hand a high-volume slice of the market to home-grown generics.